We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Genotypes and haplotypes of the VEGF gene andsurvival in locally advanced non-small cell lungcancer patients treated with chemoradiotherapy.
- Authors
Xiaoxiang Guan; Ming Yin; Qingyi Wei; Hui Zhao; Zhensheng Liu; Li-E Wang; Xianglin Yuan; O'Reilly, Michael S.; Komaki, Ritsuko; Zhongxing Liao
- Abstract
Background: Vascular endothelial growth factor (VEGF) is a major mediator of angiogenesis involving in carcinogenesis, including lung cancer. We hypothesized that VEGF polymorphisms may affect survival outcomes among locally advanced non-small cell lung cancer (LA-NSCLC) patients. Methods: We genotyped three potentially functional VEGF variants [-460 T > C (rs833061), -634 G > C (rs2010963), and +936 C > T (rs3025039)] and estimated haplotypes in 124 Caucasian patients with LA-NSCLC treated with definitive radiotherapy. We used Kaplan-Meier log-rank tests, and Cox proportional hazard models to evaluate the association between VEGF variants and overall survival (OS). Results: Gender, Karnofsky's performance scores (KPS) and clinical stage seemed to influence the OS. The variant C genotypes were independently associated with significantly improved OS (CT+CC vs. TT: adjusted hazard ratio [HR] = 0.58; 95% confidence interval [CI] = 0.37-0.92, P = 0.022), compared with the VEGF -460 TT genotype. Conclusions: Our study suggests that VEGF -460 C genotypes may be associated with a better survival of LA-NSCLC patients after chemoradiotherapy. Large studies are needed to confirm our findings.
- Subjects
LUNG cancer; VASCULAR endothelial growth factors; GENES; DRUG therapy; RADIOTHERAPY; CARCINOGENESIS
- Publication
BMC Cancer, 2010, Vol 10, p431
- ISSN
1471-2407
- Publication type
Article
- DOI
10.1186/1471-2407-10-431